Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment

Seminars in Hematology

Volumn 40, Issue 2 SUPPL. 2, 2003, Pages 80-82

  Roche Lestienne, Catherine ^b   Preudhomme, Claude ^a  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; IMATINIB; OLIGONUCLEOTIDE; ABELSON KINASE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACCURACY; ALLELE; BINDING SITE; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; DRUG BINDING; GENOTYPE; HUMAN; PATIENT SELECTION; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; DISEASE COURSE; DRUG RESISTANCE; GENETICS; MUTATION; PATHOLOGY; REVIEW;

DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MUTATION; ONCOGENE PROTEINS V-ABL; PIPERAZINES; PYRIMIDINES;

EID: 0038700992     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2003.50046     Document Type: Conference Paper

References (16)

1. Branford S, Rudzki Z, Walsh S, et al: Point mutations clustered within the ATP binding region of BCR-ABL are common in patients with emerging Glivec resistance but not in Glivec-responsive cases of CML. Blood. 98:3204, 2001 (suppl 1, abstr)
2. Branford S, Ructzki Z, Walsh S, et al: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR-ABL in leukemia who develop imatinib (STI571) resistance. Blood 99:3472-3475, 2002
3. Druker B-J, Sawyers C-L, Kantarjian H, et al: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001
4. Druker B-J, Talpaz M, Resta D-J, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
5. Gorre E-M, Mohammed M, Ellwood K, et al: Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001
6. Gorre E-M, Shah N, Ellwood K, et al: Roots of clinical resistance to STI571 cancer therapy. Science. 293:2163, 2001
7. Hochhaus A, Kreil S, Corbin A, et al: Roots of clinical resistance to STI571 cancer therapy. Science. 293:2163, 2001
8. Hofmann W-K, Jones L-C, Lemp N-A, et al: Ph (+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 as a unique BCR-ABL gene mutation. Blood 99:1860-1862, 2002
9. Kantarjian. H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652, 2002
10. Mahon F-X, Deininger M, Schultheis B, et al: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanism of resistance. Blood 96:1070-1079, 2000
11. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al: Several types of mutations of the ABL gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100:1014-1018, 2002
12. Roumiantsev S, Shah N-P, Gorre M-E, et al: Clinical resistance to the kinase inhibitor STI571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 99:107000-10705, 2002
13. Sawyers C-L, Hochhaus A, Feldman E, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood 99:3530-3539, 2002
14. Schindler T, Bornmann W, Pellicena P, et al: Structural mechanism for STI571 inhibition of Abelson tyrosine kinase. Science 289:1938-1942, 2000
15. Shah N-P, Nicoll JM, Nagar B, et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor to imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125, 2002
16. Von Bubnoff N, Schneller F, Peschel C, et al: BCR-ABL gene mutations in relation to clinical resistance of Philadelphia- chromosome-positive leukemia to STI571: A prospective study. Lancet 359:487-491, 2002